Refine your search
Collections
Co-Authors
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Sunitha Reddy, M.
- Fast Dissolving Drug Delivery System - a Review
Abstract Views :660 |
PDF Views:0
Authors
Affiliations
1 Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, IN
1 Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, IN
Source
Research Journal of Pharmacy and Technology, Vol 6, No 1 (2013), Pagination: 4-11Abstract
It is very well known that a drug can be administered through many different routes so as to produce a systemic pharmacological effect.
The main route of administrating a drug administration is the oral route which is the oldest and most commonly used because of its ease of administration, self-medication and avoidance of pain as compared to parental route. Despite of the tremendous advancement in oral route some of the people find difficultly in swallowing tablet and other oral dosage form, so in order to troubleshoot all these problem associated with oral route, fast dissolving drug delivery systems (FDDS) were first came into existence in 1970 as an alternative to tablets, syrups and capsules, for pediatric and geriatric patients which rapidly disintegrate and dissolve in saliva and then easily swallowed without need of water which is a major benefit over conventional dosage form.
The fast dissolving tablets are prepared by freeze-drying, tablet molding, spray drying, sublimation, direct compression, cotton candy process, mass-extrusion, nanonization, methods.
Formulation of oral films involves the application of both aesthetic and performance characteristics such as plasticised hydrocolloids, active pharmaceutical ingredient, taste masking agent being laminated by solvent casting or hot melt extrusion.
This review describes about the formulation methodology, evaluation parameters of fast dissolving dosage forms
Keywords
Fast Dissolving Drug Delivery System, Fast Dissolving Tablets, Fast Dissolving Films, Methods of Preparation, Evaluation Parameters
References
- Pfister W, Ghosh T, Intraoral delivery systems: An overview, current status and future trends. In Tapash Ghosh, William Pfister (Ed.), Drug Delivery to the Oral Cavity: Molecules to Market (pp.1-34). Florida: CRC Press, Taylor and Francis gp, 2005.
- Shimoda H, Taniguchi K, Nishimura M, Tsukioka K MT, Yamashita H, Inagaki N, Hirano K, Yamamot M, Kinosada Y , Itoh Y. Preparation of a fast dissolving oral thin film containing dexamethasone: A possible application to antiemesis during cancer chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 2009; 73(3): 361-365.
- Arunachalam A, Karthikeyan M, Kumar S A, Konam K, Prasad P H, Sethuraman S, Manidipa S. Fast Dissolving Drug Delivery System: A Review. Journal of Global Trends in Pharmaceutical Sciences. 2010; 1(1): 92-110.
- Garg S, Goldman D, Krumme M, Rohan L C, Smoot S, Friend D R. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Research. 2010; 88: S19-S29.
- Saini S, Nanda A, Hooda M, Komal. Fast dissolving films (FDF): innovative drug delivery system. Pharmacologyonline. 2011; 2: 919-928.
- Arun A, Amrish C. Fast Drug Delivery Systems: A Review. Der Pharmacia Lettre, 2010; 2(2): 350-361.
- Chandan S, Varun D, Ashish G, Dabeer A, Ayaj A.Orally disintegrating tablets: A review. International Journal Of Pharmacy and Life Science. 2010; 1(5):250-256.
- Advances in Formulation of Orally Disintegrating Dosage Forms: A Review Article by Rakesh Kumar Bhasin, Nirika Bhasin, Pradip Kumar Ghosh Dobetti L: Fast-Melting Tablets: Developments and Technologies. Pharm. Technol., Drug delivery supplement, 44-50, 2001.
- Masaki K: Intra Buccally Disintegrating Preparation and Production Thereof. US patent 5,466,464, 1995.
- Indurwade N.H, Rajyaguru T.H, Nakhat P.D: Novel Approach – Fast Dissolving Tablets. Indian Drugs, 39(8), 2002.
- Allen L.V, Wang B: Method of making a rapidly dissolving tablet. US Patent No. 5,635,210, 1997.
- Allen L.V, Wang B: Rapidly Dissolving Tablets. US Patent No. 5,807,576, 1998.
- Allen L.V, Wang B: Process for making a particulate support matrix for making rapidly dissolving tablets. US Patent No. 5,587,180, 1996.
- Allen L.V, Wang B: Particulate support matrix for making rapidly dissolving tablets. US Patent No.5,595,761, 1997.
- Heinemann H, Rothe W: Preparation of porous tablets. US Patent No. 3,885,026, 1975.
- Knitsch K.W: Production of porous tablets. US Patent No. 4,134,943, 1979.
- Roser B.J, Blair J: Rapidly soluble oral dosage forms, Methods of making same, and Compositions thereof. US Patent No. 5,762,961, 1998.
- Koizumi K.I.: New method of preparing high porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int. J. Pharm., 152:127-131, 1997.
- Gohel M.C, Patel M.M, Amin A.F, Agrawal R, Dave R, Bariya N.: Formulation design and optimization of mouth dissolving tablets of Nimesulide using Vacuum drying technique. AAPS Pharm. Sci. Tech., 5 (3): Article 36, 2004.
- Makino T, Yamada M, Kikuta J.I: Fast dissolving tablet and its production. US Patent No. 5,720,974, 1998.
- Fuisz et al, Easily processed tablet compositions, United States Patent 6,277,406 (Issued 21 August 2001).
- Fuisz et al, Process and apparatus for producing shear form matrix material United States Patent 6,171,607 (Issued 9 January 2001).
- Mezaache et al, Dosage form containing taste masked active agents United States Patent 6,165,512 (Issued 26 December 2000).
- Bhaskaran, S., Narmada, G.V, Indian Pharmacist, 1(2), 9-12, 2002.
- Mandel; Frederick S. et al, Orthopedic mixtures prepared by Supercritical fluid processing techniques, United States Patent 6,579,532 (Issued17 July 2003).
- Lalla. J K., Mamania, H. M., Fast dissolving rofecoxib tablets, Indian J. Pharm. Sci., 2004, 59(4), 23-26.
- Kuchekar, B. S., Mahajan, S., and Bandhan, A. C., Mouth dissolve tablets of sumatriptan, Indian Drugs, 2004,41(10), 592- 598.
- Lorenzp- Lamosa, M.L., Cuna, M., Vila-Jato, J.L. and Torres, D., J. Microencapsul., 1997, 14, 607.
- Shirai, Y., Sogo, K., Yamamoto, K., Kojima, K., Fujioka, H., Makita, H. and Nakamura,Y., Biol. Pharm. Bull, 1993, 16, 172.
- Shirai, Y., Sogo, K., Fujioka, H. and Nakamura, Y., Biol. Pharm. Bull., 17, 1994, 427. Profile Resources at Business. Com. Cima Labs - Profile. 27 May 2001.
- Makino, T., Yamada, M. and Kikuta, J., Fast dissolving tablet and its production, 1993, European Patent, http://www.business. com/ directory/ pharmaceuticals and biotech nology /drug.
- Shukla D, Chakraborty S, Singh S, Mishra B . Mouth Dissolving Tablets I: An Overview of Formulation Technology. Sci Pharm., 2009; 76: 309–326.
- Fast dissolving films: a novel approach to oral drug delivery by Aggarwal Jyoti, Singh Gurpreet ,Saini Seema Technical Brief 2010. Vol 3 Particle Sciences Drug Development Services.
- Coppens, K.A., M.J. Hall, S.A. Mitchell and M.D. Read, 2005. Hypromellose, Ethyl cellulose and Polyethylene oxide used in hot melt extrusion. Pharmaceutical Technol., pp: 1-6.
- Frey, 2006. Film Strips and Pharmaceuticals. Pharmaceutical Manufacturing and Packaging Source, pp: 92-93.
- Orally fast dissolving films as dominant dosage form for quick release by Dipika Parmar ,Dr. Upender Patel, Bhavin Bhimani, Aditi Tripathi, Dhiren Daslaniya , Ghanshyam Patel
- Drug Delivery through Osmotic Micropump - a Review
Abstract Views :575 |
PDF Views:0
Authors
Affiliations
1 Centre for Pharmaceutical Sciences, IST, JNTU, Kukatpally, Hyderabad, IN
1 Centre for Pharmaceutical Sciences, IST, JNTU, Kukatpally, Hyderabad, IN
Source
Research Journal of Pharmacy and Technology, Vol 6, No 1 (2013), Pagination: 12-16Abstract
This review article discusses the drug delivery systems using osmotic principles for pumping and some of the milestones in Osmotic Drug Delivery (ODDs) systems developed till date. Recent technological advances led to the development of low flow rate biocompatible micropumps. Drug delivery methods are considered as one of the salient characteristic feature to enhance efficacy of a drug. Micropumps help in achieving this by controlled drug delivery which is not possible in traditional methods (tablets and injections). Osmotic systems further increases the patient compliance, decreases dose related adverse events and most importantly helps in controlling or constant drug release (zero-order). Drug release from these systems is independent of pH and other physiological parameters to a large extent. Based on the potential advantages and persistent market demand for new technological advances in controlling the drug delivery rate, it is evident that osmotic pumps have bright scope in drug development.Keywords
Osmotic Pump, Drug Delivery, Zero-orderReferences
- Verma RK, et al., Osmotically controlled oral drug delivery, Drug Dev. Ind. Pharm. 26; 2000: 695–708.
- Verma RK, et al., Osmotic pumps in drug delivery, Crit. Rev. Ther. Drug Carrier Syst. 21; 2004: 477–520.
- Malaterre V, et al., Oral osmotically driven systems: 30 years of development and clinical use, Eur. J. Pharm. Biopharm. 73; 2009: 311–323.
- Gupta BP et al., Osmotically controlled drug delivery system with associated drugs, J. Pharm. Pharm. Sci. 13; 2010: 571–588.
- Babu CA, et al., Controlled-porosity osmotic pump tablets—an overview, J. Pharm. Res. Health Care 2; 2010: 114–126.
- Gosh T, Gosh A, Drug delivery through osmotic systems — an overview, J. Appl. Pharm. Sci. 1; 2011: 38–49.
- Baker R, Osmotic and mechanical devices, In: Controlled release of biologically active agents, New York, John Wiley, 1987.
- Martin A, Solution of non-electrolytes, In: Physical pharmacy 4 ed. New Delhi, BI Waverly. 1993.
- Rose S, Nelson JF, A continuous long term injector, Australian J Exp Biol. 33; 1955: 415-420.
- Jerzewski RJ, Chien YW, Osmotic drug delivery, In: Kydonieus A ed. Treatise on controlled drug delivery, New York, Marcel Dekker. 1992.
- Santus G, Waker RW, Osmotic Drug delivery: A review of the patient literature, J Control Release, 35; 1995: 1-21.
- Higuchi T, Leeper HM. ALZA corp assignee. Osmotic dispenser, US patent 3,732,865. May 15, 1973.
- Cortese R, Theeuwes F. ALZA corp assignee. Osmotic device with hydrogel driving member, US patent 4,327,725. May 4, 1982.
- Zentner GM, et al., The controlled porosity osmotic pump, J control release, 1; 1985: 269-282.
- Zentner GM, et al., Osmotic flow through controlled porosity films: an approach to delivery of water soluble compounds, J control release, 2; 1985: 217-229.
- Eckenhoff B, et al., ALZA Corp., assignee. Delivery system controlled administration of beneficial agent to ruminants. US Patent 4,595,583. Jun. 17, 1986.
- Urquhart J. Controlled drug delivery: therapeutic and pharmacological aspects. J Int Med 248; 2000:357-376.
- Urquhart J. Can drug delivery systems deliver value in the new pharmaceutical marketplace? Br J Clin Pharmacol 1997: 44413- 419.
- Wong P, et al., ALZA Corp., assignee. Osmotic dosage system for liquid drug delivery US Patent 5,413,572. May 9,1995.
- Dong L, et al., ALZA Corp., assignee. Dosage form comprising liquid formulation. US Patent 6,174,547. Jan. 16, 2001.
- Scholz OA, et al., Drug delivery from the oral cavity: focus on a novel mechatronic delivery device, Drug Discov. Today 13; 2008: 247–253.
- Goettsche T, et al., Highly integrated oral drug delivery system with valve based on electro-active-polymer, Proc. Of MEMS2007, Kobe, 2007: pp. 461–464.
- Goettsche T, Haeberle S, Integrated oral drug delivery system with valve based on polypyrrole, in: F. Carpi, E. Smela (Eds.), Biomedical Applications of Electroactive Polymer Actuators, JohnWiley & Sons, Ltd., Chichester, 2009: pp. 301–316.
- Velten T, et al., Biocompatible flow sensor with integrated solvent concentration measurement, Sens. Actuators, A 145; 2008; 257–262.
- Giannola LI, et al., New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies, Curr. Pharm. Des. 16; 2010: 653– 659.
- Moscicka AE, et al., IntelliDrug implant for medicine delivery in Alzheimer's disease treatment, Macromol. Symp. 253 (2007) 134–138.
- Ciach T, Intraoral implant for drug delivery in addiction and chronic disease treatment, Inz. Chem. Procesowa 28; 2007: 559– 565.
- Campisi G, et al., Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs, J. Control. Release 145; 2010: 214–220.
- Schumacher A., et al., Intraoral drug delivery microsystem, in: J. Vander Sloten, P. Verdonck, M. Nyssen, J. Haueisen (Eds.), ECIFMBE 2008, IFMBE Proceedings, 22, Springer, Berlin Heidelberg, 2008, pp. 2352–2355.
- A Review on Transbuccal Drug Delivery System and its Commercially Available Products
Abstract Views :497 |
PDF Views:0
Authors
Affiliations
1 Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, IN
1 Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, IN
Source
Research Journal of Pharmacy and Technology, Vol 6, No 1 (2013), Pagination: 22-28Abstract
Buccal route is one of the promising area where continuous research is going on in order to increase the bioavailability of most of the drugs effected by first pass metabolism and also to increase possibility of oral delivery of protein and peptide drugs with high patient compliance. In order to achieve the required target of bioavailability, drugs are formulated in different buccal dosage forms. The objective of this article is to enlighten the commercial products of various buccal dosage forms and their evaluation.Keywords
Buccal Route, First Pass Metabolism, Bioavailability, Oral Mucosa, Marketed ProductsReferences
- Buccal drug delivery system in N.K. Jain: Advances in controlled and novel drug delivery system 1 st ed: pp 78-80
- www.medicines.org.uk
- Spiegeleer BD et al. Dissolution stability and IVIVC investigation of a buccal tablet. Anal Chim Acta. 2001; 446: 345- 351
- Kerec M. et al. Mucoadhesion on pig vesical mucosa: Influence of polycarbophil/calcium interactions. Int J Pharm. 2002; 241: 135-143.
- Wong C.F, Yuen K.H, Peh K.K, Formulation and evaluation of controlled release Eudragit buccal patches. International Journal of Pharmaceutics, 178: 11-22, 1999.
- Nafee N.A, Ismail F, Boraie N, Mortada L, Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm, 53: 199-212.
- Patel V.M, Prajapati B.G, Patel M.M, Design and characterization of chitosan containing mucoadhesive buccal patches of propranolol hydrochloride. Acta Pharm, 57: 61-72, (2007).
- Luana Perioli et al , Development of mucoadhesive patches for buccal administration of ibuprofen. J. Contr. Rel., 2004; 99:73- 82.
- . Kusum Devi V et al., Design and Evaluation of Matrix diffusion Controlled Transdermal patches of Verapamil Hydrochloride, Drug Dev Ind Pharm 2003; 29(5):495-503.
- Shojaei, A.H. and Li, X. Mechanisms of buccal mucoadhesion of novel copolymers of acrylic acid and polyethylene glycol monomethylether monomethacrylate, J. Control. Rel., 47:151- 161, 1997.
- http://www.igenericdrugs.com
- www.generex.com
- http://www.hc-sc.gc.ca
- Siddiqui MN, Garg G, Sharma PK, Fast dissolving tablets: Preparation, characterization and evaluation: An overview, International Journal of Pharmaceutical Sciences Review and Research, 2010, 4 (2).
- Felton L., P. O'Donnell and J. McGinity, Mechanical dispersions, in: Aqueous polymeric coatings pharmaceutical dosage forms, 3rd edition, J. Mc Ginity, L. Felton (Eds), Vol. 176, Drugs and the electronic tongue to optimize taste masking in a Pharmaceutical Sci., pp: 108.
- Novel Approaches for Delivery of Proteins and Peptides – A Review
Abstract Views :501 |
PDF Views:0
Authors
M. Sunitha Reddy
1,
Sama Mallikarjun Reddy
1,
A. Mahesh Chandra
1,
B. Sai Santhosh
1,
Ch. Surekha
1,
K. Naveen
1
Affiliations
1 Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, IN
1 Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 5, No 1 (2013), Pagination: 7-11Abstract
Peptides are short polymers of amino acids (usually less than or equal to 100) joined together by peptide bonds and comprise some of the basic components of human biological processes, including enzymes, hormones, and antibodies. The link between one amino acid residue and the next is known as a peptide bond. Proteins are typically much longer chains of (greater than 100) amino acids similarly linked by peptide bonds. These polypeptides and proteins play an important role in functioning of vital organs. They are involved in structural, signalling and enzymatic functions. A simple change in the protein structure can trigger functions, such as signalling, targeting, catalysis, catabolism, modification of circulation time in the body and immunogenicity. They are used for systemic treatment of certain disease. As the modern genomic and proteomic technology enables rapid screening of novel proteins and peptides as potential drug candidates, design of delivery systems for these biologics remains challenging especially to achieve site specific pharmacological actions. This article discusses the issues associated with targeted delivery of protein and peptide drugs.Keywords
Peptides, Proteins, Drug Delivery, Site Specific, Genomic and Proteomic Technology, Targeted Delivery.References
- Leichtersis: The business of insulin: a relationship between innovation and economics: Clin Diabetes (2003 21:40-42)
- Med. Ad. News, May (2004) 23(5):70-72
- Sally-Ann Cryan1 Carrier-based Strategies for Targetin Protein and Peptide Drugs to the Lungs. The AAPS Journal 2005: 7 (1) Article 4.
- Graham.L.M. (2003) PEGASPARAGINASE: a review of clinical stadies.Adv.Drug Devil. Rev.55,1293-1302
- Levy,Y.et al.(1998) Adenosine deaminase deficiency with late onset or recurrent Infections: response to treatment with polyethylene glycol modified adenosine deminase.J.pediatr.113,312-317
- Bailon,P.el al.(2001) Rational design of potent, long lasting form of interferon: a 40kDa branched poly-ethylene glycolconjugated interferon alpha-2a for the treatment of Hepatitis C. Bioconjug. Chem.12,195-202
- Wang,Y.S.et al.(2002) Structural and biological characterisation of pegylated Recombinant interferon -2b and therapeutic implications. Adt.Durg Devil. Rev.54,547- 570
- Wong S.S. (1991) Reactive groups of proteins and their modifying agents. In Chemistry of Protein conjugation and cross-linking, p.13, CRC press 46 The EyeTech Study Group (2002) Preclinical andphase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22,143-152
- Vyas TK. Foundation and physiological factors influencing CNS delivery upon intranasal administration. Crit Rev Ther Drug Carrier Syst 2006;23:319-47.
- Trainer, P.J.et.al.(2000) Treatment of acromegaly with the growth hormone-receptor Antagonist pegvisomant. N.Engl. J.Med.342,1171-1171
- Vladimir Torchilin ; Intracellular delivery of protein and peptide therapeutics. Elsevier Drug Discovery Todays Technologies, volume xxx., No.xx 2009
- Desi MP,Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent Pharm res 97;14:1568-73.
- Pan Y. Bioadhesive polysaccharide in protein drug delivery system: Chitosan nanoparticles improve absorption of insulin in vivo. Int J Pharm 2002;249:139-47
- Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: Barriers and Developments. Bio Drugs 2005;19:165-77.
- Jitendra, Sharma PK, Bansal S, Banik A. Noninvasive routes of proteins and peptides drug delivery. Indian J Pharm Sci 2011;73:367-75
- Spiegelmen AR. Treatment of diabetes with synthetic vasopressin. J Am Med Assoc 1983;184:657-8.
- Wuthrich P, Martenet M, Buri P. Effect of formulation additives upon the intranasal bioavailability of a peptide drug: Tetracosactide (ACTHi-24). Pharm Res 1994;11:278-82.
- Illum L, Fisher AN, Jabbal-Gill I, Davis SS. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J pharm 2001;222:109-19.
- Szewczuk MR, Campbell RJ, Jung LK, Lack of age-associated immune dysfunction in mucosal-associated lymph nodes. J Immunol 1981;126:2200-4.
- Ugwoke MI Development and Evaluation of controlled Release Nasal Drug Delivery Systems of Apomorphine Leuven, Belgium: Leuven University Press; 1999.
- Senel S, Kremer M, Katalin N, Squier C. Delivery of Bioactive Peptides and Proteins Across Oral (Buccal) Mucosa current pharmaceutical biotechnology, Volume 2, Number 2, June 2001, pp. 175-186(12).
- Pillai O, Borkute SD, Sivaprasad N, Panchagnula R. Transdermal iontophoresis of insulin: 11. Physicochemical considerations. Int J Pharm 2003;254:271-80.
- Langkjaer L, Brange J, Grodsky GM, Guy RH. Iontophoresis of monomeric insulin analogues In vitro: Effects of insulin charge and skin pretreatment. J Control Release 1998;51:47-56.
- Banga AK, Chein YM. Charecterization of in vitro transdermal iontophoretic delivery of insulin, Drug Dev Ind Pharm 1999;19:2069-87.
- Brown L, Rashba-Step J, Scott T. Pulmonary delivery of novel insulin microspheres. In: Dalby R, Byron PR, Peart J, Farr SJ, editors. Respiratory Drug Delivery X111. Raleigh. NC: Davis Horwood International Publishing; 2002. P. 431-3.
- Byron PR. Drug delivery devices: Issues in drug development. Proc Am Thorac Soc 2004;1:321-8.